Home / Resource Library / Real World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell LymphomaReal World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma ASH 2021